4-(4-chlorophenyl)piperazin-2-one | 1121771-24-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪烷类
• 英文名称: 4-(4-chlorophenyl)piperazin-2-one
• CAS: 1121771-24-1
• 化学式: C₁₀H₁₁ClN₂O
• 分子量: 210.663
• InChiKey: MTOSLLBIRLUGIF-UHFFFAOYSA-N

物化性质

• 沸点：
  447.8±40.0 °C(Predicted)
• 密度：
  1.267±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.8
• 重原子数：
  14
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.3
• 拓扑面积：
  32.3
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  4-(4-chlorophenyl)piperazin-2-one 、 溴乙酸乙酯 在 sodium hydride 作用下， 以 四氢呋喃 为溶剂， 反应 1.5h， 以74%的产率得到Ethyl 2-[4-(4-chlorophenyl)-2-oxopiperazin-1-yl]acetate
  参考文献：
  名称：

  EP2184272

  摘要：

  公开号：
• 作为产物：
  描述：

  2-哌嗪酮 、 4-溴氯苯 在 sodium t-butanolate 作用下， 反应 0.5h， 以29%的产率得到4-(4-chlorophenyl)piperazin-2-one
  参考文献：
  名称：

  EP2184272

  摘要：

  公开号：

文献信息

• [EN] COMPOSITION AND METHODS OF USE OF SMALL MOLECULES AS BINDING LIGANDS FOR THE MODULATION OF PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9(PCSK9) PROTEIN ACTIVITY<br/>[FR] COMPOSITION ET PROCÉDÉS D'UTILISATION DE PETITES MOLÉCULES EN TANT QUE LIGANDS DE LIAISON POUR LA MODULATION DE L'ACTIVITÉ PROPROTÉINE CONVERTASE SUBTILISINE/PROTÉINE KEXINE DE TYPE 9 (PCSK9)
  申请人：SRX CARDIO LLC

  公开号：WO2016029037A1

  公开（公告）日：2016-02-25

  This invention is related to the field of PCSK9 biology and the composition and methods of use of small molecule ligands for modulation of PCSK9 biological activity. In particular, the invention provides compositions of small molecule compounds that modulate circulating levels of low density lipoproteins by altering the conformation of the protein PCSK9. Binding these small molecule ligands to PCSK9 alters the conformation of the protein, modifying the interaction between PCSK9 and an endogenous low density lipoprotein receptor, and can lead to reduced or increased levels of circulating LDL-cholesterol. High LDL-cholesterol levels are associated with increased risk for heart disease. Low LDL-cholesterol levels may be problematic in other conditions, such as liver dysfunction; thus, there is also utility for small molecule ligands that can raise LDL levels.

  这项发明涉及PCSK9生物学领域，以及用于调节PCSK9生物活性的小分子配体的组成和使用方法。具体而言，该发明提供了调节低密度脂蛋白循环水平的小分子化合物组合物，通过改变蛋白质PCSK9的构象来实现。将这些小分子配体与PCSK9结合会改变蛋白质的构象，修改PCSK9与内源性低密度脂蛋白受体之间的相互作用，并可能导致循环LDL胆固醇水平降低或增加。高LDL胆固醇水平与心脏疾病风险增加相关。低LDL胆固醇水平在其他情况下可能会有问题，比如肝功能障碍；因此，开发能够提高LDL水平的小分子配体也具有实用性。
• PIPERAZINE DERIVATIVE
  申请人：Shionogi&Co., Ltd.

  公开号：EP2184272A1

  公开（公告）日：2010-05-12

  A compound which specifically binds to a receptor of NR1/ NR2B, and is used as a NR2B receptor antagonist is provided. It has been found out that a piperazine derivative represented by the formula (I) binds specifically to a receptor of NR1/NR2B, and is used as a NR2B receptor antagonist. A compound represented by: wherein R1 is each independently C1-C3 alkyl or the like, m is an integer of 0 to 4, X is -N(R4)-C(=O)-C(=O)-, -N(R4)-(CR5R6)p-C(=O)-, -N(R4)-C(-O)-(CR7R8)q- or -C(=O)-N(R4)-(CR7R8)q-, p and q are each independently an integer of 1 to 3, R4, R5, R6, R7 and R8 are each independently a hydrogen atom or lower alkyl, A1 is benzoxazolinone or the like, and A2 is optionally substituted phenyl or the like, or a pharmaceutically acceptable salt or a solvate thereof.

  提供了一种能与 NR1/ NR2B 受体特异性结合并用作 NR2B 受体拮抗剂的化合物。 研究发现，由式（I）代表的哌嗪衍生物能与 NR1/NR2B 受体特异性结合，并可用作 NR2B 受体拮抗剂。 由以下式子代表的化合物 其中 R1 各自独立地为 C1-C3 烷基或类似物，m 为 0 至 4 的整数，X 为-N(R4)-C(＝O)-C(＝O)-、-N(R4)-(CR5R6)p-C(＝O)-、-N(R4)-C(-O)-(CR7R8)q-或-C(＝O)-N(R4)-(CR7R8)q-，p 和 q 各自独立地为 1 至 3 的整数、R4、R5、R6、R7 和 R8 各自独立地为氢原子或低级烷基，A1 为苯并恶唑啉酮或类似物，A2 为任选取代的苯基或类似物，或其药学上可接受的盐或溶液。
• Composition and methods of use of small molecules as binding ligands for the modulation of proprotein convertase subtilisin/kexin type 9(PCSK9) protein activity
  申请人：SRX CARDIO, LLC

  公开号：US10034892B2

  公开（公告）日：2018-07-31

  This invention is related to the field of PCSK9 biology and the composition and methods of use of small molecule ligands for modulation of PCSK9 biological activity. In particular, the invention provides compositions of small molecule compounds that modulate circulating levels of low density lipoproteins by altering the conformation of the protein PCSK9. Binding these small molecule ligands to PCSK9 alters the conformation of the protein, modifying the interaction between PCSK9 and an endogenous low density lipoprotein receptor, and can lead to reduced or increased levels of circulating LDL-cholesterol. High LDL-cholesterol levels are associated with increased risk for heart disease. Low LDL-cholesterol levels may be problematic in other conditions, such as liver dysfunction; thus, there is also utility for small molecule ligands that can raise LDL levels.

  本发明涉及 PCSK9 生物学领域以及用于调节 PCSK9 生物活性的小分子配体的组成和使用方法。特别是，本发明提供了通过改变蛋白质 PCSK9 的构象来调节循环中低密度脂蛋白水平的小分子化合物组合物。将这些小分子配体与 PCSK9 结合可改变该蛋白的构象，改变 PCSK9 与内源性低密度脂蛋白受体之间的相互作用，并可导致循环中低密度脂蛋白胆固醇水平的降低或升高。低密度脂蛋白胆固醇水平高与心脏病风险增加有关。低密度脂蛋白胆固醇水平过低可能会对肝功能障碍等其他疾病造成困扰；因此，能提高低密度脂蛋白水平的小分子配体也很有用。
• Method to treat lipid dysregulation by modulation of proprotein convertase subtilisin/kexin type 9 (PCSK9) protein activity with small molecule ligands
  申请人：SRX CARDIO, LLC

  公开号：US11026957B2

  公开（公告）日：2021-06-08

  This invention is related to the field of PCSK9 biology and the composition and methods of use of small molecule ligands for modulation of PCSK9 biological activity. In particular, the invention provides compositions of small molecule compounds that modulate circulating levels of low density lipoproteins by altering the conformation of the protein PCSK9. Binding these small molecule ligands to PCSK9 alters the conformation of the protein, modifying the interaction between PCSK9 and an endogenous low density lipoprotein receptor, and can lead to reduced or increased levels of circulating LDL-cholesterol. High LDL-cholesterol levels are associated with increased risk for heart disease. Low LDL-cholesterol levels may be problematic in other conditions, such as liver dysfunction; thus, there is also utility for small molecule ligands that can raise LDL levels.

  本发明涉及 PCSK9 生物学领域以及用于调节 PCSK9 生物活性的小分子配体的组成和使用方法。特别是，本发明提供了通过改变蛋白质 PCSK9 的构象来调节循环中低密度脂蛋白水平的小分子化合物组合物。将这些小分子配体与 PCSK9 结合可改变该蛋白的构象，改变 PCSK9 与内源性低密度脂蛋白受体之间的相互作用，并可导致循环中低密度脂蛋白胆固醇水平的降低或升高。低密度脂蛋白胆固醇水平高与心脏病风险增加有关。低密度脂蛋白胆固醇水平过低可能会对肝功能障碍等其他疾病造成困扰；因此，能提高低密度脂蛋白水平的小分子配体也很有用。
• COMPOSITION AND METHODS OF USE OF SMALL MOLECULES AS BINDING LIGANDS FOR THE MODULATION OF PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9(PCSK9) PROTEIN ACTIVITY
  申请人：SRX Cardio, LLC

  公开号：EP3182971A1

  公开（公告）日：2017-06-28